Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results80% success

Data Visualizations

Phase Distribution

5Total

Not Applicable (3)

P 1 (1)

P 2 (1)

Trial Status

Completed4

Terminated1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (5)

Showing 5 of 5 trials

NCT05168657Not ApplicableCompleted

Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth

NCT04503564Not ApplicableCompleted

"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)

NCT04591925Not ApplicableTerminated

SteadiSet™ Pilot Study (SteP Study)

NCT01781975Phase 2Completed

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT01772251Phase 1CompletedPrimary

Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study

Showing all 5 trials

Diabetes Mellitus, Insulin-Dependent, 1